bioMerieux

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Type
Public
HQ
Marcy L'Étoile, FR
Founded
1963
Size (employees)
9,376 (est)
bioMerieux was founded in 1963 and is headquartered in Marcy-l'Étoile, FR

bioMerieux Office Locations

bioMerieux has an office in Marcy-l'Étoile
Marcy L'Étoile, FR (HQ)
376 Chemin De L'orme

bioMerieux Data and Metrics

bioMerieux Financial Metrics

bioMerieux's revenue was reported to be €2.1 b in FY, 2016 which is a 7% increase from the previous period.
€, EUR

Revenue (FY, 2016)

2.1 b

Revenue growth (FY, 2015 - FY, 2016), %

7%

Gross profit (FY, 2016)

1.1 b

Gross profit margin (FY, 2016), %

52%

Net income (FY, 2016)

179.2 m

EBIT (FY, 2016)

282.5 m

Market capitalization (23-Jun-2017)

7.7 b

Closing share price (23-Jun-2017)

197.5

Cash (31-Dec-2016)

178.6 m

EV

8 b
bioMerieux's current market capitalization is €7.7 b.
€, EURFY, 2014FY, 2015FY, 2016

Revenue

1.7 b2 b2.1 b

Revenue growth, %

16%7%

Cost of goods sold

853.9 m975.4 m1 b

Gross profit

844.5 m989.2 m1.1 b

Gross profit Margin, %

50%50%52%

Sales and marketing expense

311.3 m365.4 m402.1 m

R&D expense

205.8 m238.9 m271.9 m

General and administrative expense

141.7 m163.8 m167.4 m

Operating expense total

658.8 m768.1 m841.4 m

EBIT

203.6 m194.9 m282.5 m

EBIT margin, %

12%10%13%

Interest expense

7.2 m24.6 m17.6 m

Income tax expense

51.7 m65.9 m79.8 m

Net Income

135.5 m110.3 m179.2 m
€, EURFY, 2014FY, 2015FY, 2016

Cash

119.7 m147.1 m178.6 m

Accounts Receivable

449.3 m445.1 m465.8 m

Inventories

299.2 m355.8 m404.4 m

Current Assets

991.4 m1.1 b1.2 b

PP&E

486.9 m573.6 m734.5 m

Goodwill

437.8 m459.3 m470.6 m

Total Assets

2.6 b2.8 b3 b

Accounts Payable

188.9 m176.9 m175.6 m

Total Debt

369.2 m370.7 m453.3 m

Current Liabilities

611.5 m683.5 m759.8 m

Non-Current Liabilities

556.2 m582 m647.6 m

Common Stock

12 m12 m12 m

Additional Paid-in Capital

1.2 b1.4 b1.4 b

Total Equity

1.4 b1.5 b1.6 b

Debt to Equity Ratio

0.3 x0.2 x0.3 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x

Financial Leverage

1.9 x1.8 x1.9 x
€, EURFY, 2014FY, 2015FY, 2016

Net Income

135.5 m110.3 m179.2 m

Cash From Operating Activities

298.3 m310 m335.6 m

Purchases of PP&E

(158.1 m)(208.2 m)(233 m)

Cash From Investing Activities

(502.7 m)(208 m)(257.2 m)

Cash From Financing Activities

(83.4 m)(62.1 m)(52.5 m)
€, EURY, 2016

EV/EBIT

28.4 x

EV/CFO

23.9 x

Revenue/Employee

224.3 k

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

1.9 x

bioMerieux Operating Metrics

bioMerieux's Facilities was reported to be 19 in FY, 2016
FY, 2015FY, 2016

Patent Families

581529

Countries

150

Facilities

19

bioMerieux Market Value History

bioMerieux Online and Social Media Presence

bioMerieux Company Life and Culture

You may also be interested in